This Biotech Business Won't Let Cost Get in the Way of a Covid Cure
Synthetic gene manufacturer ATUM turned down venture capital. That's why it's free to do whatever it takes to fight Covid-19. The nice thing about forgoing venture money as a biotech firm is that when a pandemic devastates the globe you can leave millions of dollars of revenue on the table in order …
Inc Magazine flipped this story into Big Heroes of Small Business•1345d